IDEXX LABORATORIES INC. $98 (Nasdaq symbol IDXX; Aggressive Growth Portfolio, Manufacturing & Industry sector; Shares outstanding: 52.5 million; Market cap: $5.1 billion; Price-to-sales ratio: 4.1; No dividends paid; TSINetwork Rating: Average; www.idexx.com) gets 85% of its sales by making equipment that veterinarians use to detect diseases in pets. The remaining 15% comes from sales of systems that detect contaminants in livestock, water and dairy products.
Idexx is benefiting as the improving economy encourages people to take their pets to the vet more often. That has pushed up sales of Idexx’s equipment, such as its Pro-Cyte Dx hematology analyzer, which processes animal blood tests in just two minutes.
Rising equipment sales have also spurred higher demand for consumables, such as test tubes and slides, that veterinarians must constantly replenish.
In the quarter ended June 30, 2013, Idexx’s revenue rose 5.0%, to $352.6 million from $335.6 million a year earlier. That’s mainly due to higher demand for consumables. The company also raised these products’ prices.
Earnings rose 5.2%, to $54.0 million from $51.3 million. Per-share earnings gained 8.8%, to $0.99 from $0.91, on fewer shares outstanding.
Idexx spent $22.2 million, or 6.3% of its revenue, on research in the latest quarter. That’s up 10.6% from $20.1 million, or 6.0% of revenue, a year earlier. This spending is helping it develop products and services that will help it keep its leading market share.
For example, the company’s VetConnect Plus service lets veterinarians easily view an animal’s medical history over the Internet and share this information with other vets. This helps reduce errors and speeds up treatment. Over 8,500 vets in the U.S. and Canada now use this service, and Idexx plans to make it available in the U.K. and Australia in 2014.
The company can easily afford to keep investing in new products. It holds cash of $251.0 million, or $4.77 a share, and its long-term debt is just $884,000.
Idexx should earn $3.47 a share in 2013. However, the stock is expensive at 28.2 times that estimate.
Idexx is a hold.